CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?
Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR-positive breast cancer.
Chemotherapy is the best option for the initial management of metastatic prostate cancer.
Abiraterone has become the first-choice treatment for men with metastatic prostate cancer.
Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
In this review, we highlight prospective data on checkpoint inhibition alone and in combination, discuss data regarding the efficacy and toxicity of combination therapy, and identify clinical scenarios that may favor treatment with combination therapy.
Here, we discuss how to improve adherence to endocrine therapy in women with HR-positive breast cancer, as well as the side effects and the reasons for discontinuation.
Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors
A 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus, and he was an active smoker with a 27 pack-year history.
In this Q&A, we discuss the research into the relationships between gut microbiota, diet, and colorectal cancer.
This article provides guidance to oncology clinicians on vaccine recommendations and safety of use in their patients.
Implications of Mutation Profiling in Myeloid Malignancies—PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies
In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases.